New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:31 EDTMNK, ZGNXMallinckrodt, Zogenix to end co-promotion agreement
Mallinckrodt (MNK) announced a mutually-agreed upon end of the company’s co-promotion agreement with Zogenix (ZGNX). The co-promotion agreement covered SUMAVEL DosePro, a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches. Mallinckrodt’s promotion of SUMAVEL DosePro will end January 31. Mallinckrodt and Zogenix entered into the co-promotion agreement June 7, 2012. Under terms of the agreement, Mallinckrodt’s U.S. sales force sold SUMAVEL DosePro to its customer base of prescribers. Zogenix continued to record all product revenues and Mallinckrodt was compensated based on a percentage of net sales from prescriptions generated by Mallinckrodt. The original agreement was to have run through June 30, 2014.
News For MNK;ZGNX From The Last 14 Days
Check below for free stories on MNK;ZGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
07:36 EDTMNKMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
16:13 EDTMNKMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
16:09 EDTMNKMallinckrodt initiated with an Outperform at Oppenheimer
Target $100.
July 14, 2014
15:09 EDTMNKQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
08:36 EDTZGNXZogenix announces patent for DosePro Needle-free Delivery System
Subscribe for More Information
07:04 EDTMNKMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
July 11, 2014
06:39 EDTMNKQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
July 9, 2014
08:33 EDTZGNXZogenix reports positive development on U.S. District Court ruling
Zogenix commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict access to Zohydro ER Extended-Release Capsules, CII, violates Constitutional law. The court's decision supports the importance of upholding the principle at the heart of this case, which is that the FDA is the only regulatory body that is authorized to determine the approval and access of medicines for all Americans. On October 25, 2013, the FDA approved Zohydro ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, and today's decision preserves access for those in Massachusetts who may benefit from its medical attributes and sets a precedent for other states seeking to unjustly restrict access to Zohydro ER. Zogenix will continue to work to ensure patients have access to Zohydro ER in every state in a manner that is consistent with all extended-release opioids.
July 8, 2014
14:15 EDTZGNXZogenix motion in suit with Massachusetts allowed in part, denied in part
A judge in the U.S. district court for Massachusetts allowed in part and denied in part Zogenix's motions in its battle with the state over regulations that Massachusetts is seeking to impose on the sales of its pain drug, Zohydro ER. The judge ruled that the company has stated a plausible claim for relief and the state's motion to dismiss was denied without prejudice. The company's motion to preliminarily enjoin the “LMN regulation” was allowed, but Zogenix has not met its burden of proof on the “pharmacist-only regulation” and its motion for a preliminary injunction on that regulation was denied without prejudice to renewal upon a more detailed submission, the judge wrote in the ruling. Note that shares of Zogenix remain down about 9% in afternoon trading, after its competitor, Purdue Pharma, announced earlier today that the FDA has granted Priority Review designation for its once-daily, single-entity hydrocodone bitartrate tablet, which competes with Zohydro ER. Reference Link
13:48 EDTZGNXZogenix drops 10% after competitor gets Priority Review
Shares of Zogenix (ZGNX) are moving lower after Purdue Pharma announced earlier today that the FDA has granted Priority Review designation for its once-daily, single-entity hydrocodone bitartrate tablet. The investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse, Purdue stated. Shares of Zogenix, which has a competing pain killer drug called Zohydro ER without abuse-deterrent properties, are down 10%, or 22c, to $1.91 in afternoon trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use